Author | Gregory Rossi, PhD

Articles

Clinical Trial Simulation of a 200-µg Fixed Dose of Darbepoetin Alfa in Chemotherapy-Induced Anemia

October 01, 2002

Our objective was to assess, using clinical trial simulation, the feasibility of a fixed 200-µg dose of darbepoetin alfa (Aranesp) administered every 2 weeks in chemotherapy-induced anemia. A pharmacokinetic/pharmacodynamic

Darbepoetin Alfa: Impact on Treatment for Chemotherapy-Induced Anemia and Considerations in Special Populations

October 01, 2002

ByJohan Vansteenkiste, MD, PhD

Erik Poulsen, MS

Gregory Rossi, PhD

John Glaspy, MD, MPH

Our objective was to evaluate the effects of darbepoetin alfa (Aranesp) on hemoglobin and transfusions in anemic patients with cancer undergoing chemotherapy, and the impact of age, sex, baseline hemoglobin, chemotherapy

Every-2-Week Darbepoetin Alfa Is Comparable to rHuEPO in Treating Chemotherapy-Induced Anemia

October 01, 2002

ByBarry Mirtsching, MD

Veena Charu, MD

Saroj Vadhan-raj, MD

Alan B. Colowick, MD, MPH

Gregory Rossi, PhD

Dianne Tomita, MPH

William P. Mcguire Iii, MD

The safety and efficacy of darbepoetin alfa (Aranesp) at 3.0 µg/kg administered every 2 weeks and recombinant human erythropoietin (rHuEPO) given as 40,000 U weekly or 150 U/kg three times weekly were evaluated by